Chen Ying, Zhang Lei, Liu Wenxin, Liu Xiangyu
Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China ; Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China ; National Clinical Research Centre of Cancer, Tianjin 300060, China.
Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Biomed Res Int. 2015;2015:589301. doi: 10.1155/2015/589301. Epub 2015 Nov 1.
Tumor-stroma ratio (TSR) has recently been identified as a promising prognostic parameter for several solid tumors. This study aimed to evaluate the prognostic role of TSR in epithelial ovarian cancer (EOC) and 838 EOC patients were enrolled in this study. TSR was estimated on hematoxylin-and-eosin-stained tissue sections from the most invasive part of the primary tumor. Patients were classified as stroma-rich or stroma-poor according to the proportion of stroma ≥50% or <50%. Chi-square test analysis revealed that TSR were significantly associated with FIGO stage, LN status, and recurrence or not (all of them P < 0.001). The higher stroma-rich proportions were found in EOC patients with advanced stage (36.13% versus 19.75%), LN metastasis (51.93% versus 27.25%), and recurrence (34.27% versus 6.82%). Stroma-rich EOC patients had obvious shorter median time of progression-free survival (29 versus 39 months) and overall survival (50 versus 58 months), respectively. TSR was an independent prognostic factor for the evaluation of PFS in EOC. Stroma-rich tumors had worse prognosis and higher risk of relapse compared with those in stroma-poor tumors in EOC patients. Considered easy to determine for routine pathological examination, TSR may serve as a new prognostic histological parameter in EOC.
肿瘤-基质比（TSR）最近已被确定为几种实体瘤有前景的预后参数。本研究旨在评估TSR在上皮性卵巢癌（EOC）中的预后作用，本研究纳入了838例EOC患者。在苏木精-伊红染色的原发肿瘤最具侵袭性部分的组织切片上评估TSR。根据基质比例≥50%或<50%，将患者分为基质丰富型或基质贫乏型。卡方检验分析显示，TSR与国际妇产科联盟（FIGO）分期、淋巴结状态以及是否复发显著相关（所有P<0.001）。在晚期EOC患者（36.13%对19.75%）、有淋巴结转移的患者（51.93%对27.25%）和复发患者（34.27%对6.82%）中发现基质丰富比例更高。基质丰富的EOC患者的无进展生存期（29个月对39个月）和总生存期（50个月对58个月）的中位时间明显更短。TSR是评估EOC患者无进展生存期的独立预后因素。与EOC患者中基质贫乏的肿瘤相比，基质丰富的肿瘤预后更差，复发风险更高。考虑到TSR易于通过常规病理检查确定，它可能作为EOC一种新的预后组织学参数。
